# H \$90.00 45

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

ETAS ID: TM775946

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	First Amendment to IP Security Agreement

#### **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
KALA PHARMACEUTICALS, INC.		12/19/2022	Corporation: DELAWARE

#### **RECEIVING PARTY DATA**

Name:	OXFORD FINANCE LLC
Street Address:	115 South Union Street
Internal Address:	Suite 300
City:	Alexandria
State/Country:	VIRGINIA
Postal Code:	22314
Entity Type:	Limited Liability Company: DELAWARE

#### **PROPERTY NUMBERS Total: 3**

Property Type	Number	Word Mark
Registration Number:	4585580	KALA
Registration Number:	5401810	KALA
Serial Number:	90749282	ZUDREYA

### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Email:** bethany.stokes@gtlaw.com

Correspondent Name: Bethany A. Stokes
Address Line 1: Greenberg Traurig, LLP

Address Line 2: One International Place, Suite 2000
Address Line 4: Boston, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	138179.019300
NAME OF SUBMITTER:	Bethany A. Stokes
SIGNATURE:	/Bethany A. Stokes/
DATE SIGNED:	12/22/2022

**Total Attachments: 30** 

source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page1.tif

source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page2.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page3.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page4.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page5.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page6.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page7.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page8.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page9.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page10.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page11.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page12.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page13.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page14.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page15.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page16.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page17.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page18.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page19.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page20.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page21.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page22.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page23.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page24.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page25.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page26.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page27.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page28.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page29.tif source=Oxford (Kala) - Kala Pharmaceuticals First Amendment to IP Security Agreement (Executed)#page30.tif

#### FIRST AMENDMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT

This First Amendment to Intellectual Property Security ("First Amendment") is entered into as of December 19, 2022 (First Amendment Date") by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 ("Oxford") as collateral agent (in such capacity, "Collateral Agent"), the Lenders described in that certain Loan and Security Agreement, dated as of May 4, 2021 (as amended, modified or supplemented from time to time, the "Loan Agreement") from time to time, including Oxford in its capacity as a Lender (each a "Lender" and collectively, the "Lenders), and KALA PHARMACEUTICALS, INC., a Delaware corporation with an address located at 1167 Massachusetts Ave., Arlington, MA 02476 ("Grantor"). Collateral Agent, Grantor are sometimes referred to herein collectively as the "Parties," and individually as a "Party."

WHEREAS, the Parties and Combangio, Inc. have entered into the Loan Agreement pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms thereof;

WHEREAS, in connection with the Loan Agreement, on May 4, 2021, the Parties entered into that certain Intellectual Property Security Agreement ("IPSA") pursuant to which Grantor granted to Collateral Agent, for the ratable benefit of the Lenders, a security interest in the Intellectual Property Collateral;

WHEREAS, the IPSA was recorded with the Patent Division and Trademark Division of the United States Patent and Trademark Office on May 6, 2021, at Reel/Frame 056168/0602 and Reel/Frame 007282/0798, respectively, to evidence the security interest granted under the IPSA;

WHEREAS, the Parties entered into that certain Release of Security Interest in Certain Intellectual Property on July 8, 2022 (the "Partial Release") pursuant to which Collateral Agent agreed to release, discharge, terminate and cancel its security interest in certain Intellectual Property Collateral;

WHEREAS, the Partial Release was recorded with the Patent Division and Trademark Division of the United States Patent and Trademark Office on July 8, 2022, at Reel/Frame 060614/0713 and Reel/Frame 007773/0895, respectively, to evidence the release granted under the Partial Release; and

WHEREAS, the Parties desire to amend certain provisions of the IPSA as provided herein and subject to the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:

- 1. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Loan Agreement.
- 2. Exhibit B of the IPSA is hereby amended and restated in its entirety as set forth in Exhibit A attached hereto.
- 3. Exhibit C of the IPSA is hereby amended and restated in its entirety as set forth in Exhibit B attached hereto.

- 4. To induce Collateral Agent and Lenders to enter into this First Amendment, Grantor hereby represents and warrants to Collateral Agent and Lenders as follows that set forth on Exhibit A and Exhibit B is a complete and current list of Grantor's Patents and Trademarks, respectively, on the date hereof.
- 5. Except as expressly set forth herein, the IPSA shall continue in full force and effect without alteration or amendment. This First Amendment is, and shall be considered for all purposes, a Loan Document and this First Amendment together with the other Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.
- 6. This First Amendment shall be deemed effective as of the First Amendment Date upon the due execution and delivery to Collateral Agent of this First Amendment by each Party hereto.
- 7. This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.
- 8. This First Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.

[Remainder of page left intentionally blank]

IN WITNESS WHEREOF, the parties have caused this First Amendment to Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

	GRANTOR:
	KALA PHARMACEUTICALS, INC.
Address of Grantor:	
1167 Massachusetts Ave. Arlington, MA 02476	By Eric Traditenberg  Name: Eric Trachtenberg
Attn: Eric Trachtenberg	Title: General Counsel and Secretary
	COLLATERAL AGENT:
Address of Collateral Agent:	OXFORD FINANCE LLC
115 South Union Street	
Suite 300	The state of the s
Alexandria, VA 22314	By
Attn: Legal Department	Name:
	Title:

IN WITNESS WHEREOF, the parties have caused this First Amendment to Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

	GRANTOR:
	KALA PHARMACEUTICALS, INC.
Address of Grantor:	
1167 Massachusetts Ave. Arlington, MA 02476 Attn: Eric Trachtenberg	By Name: Eric Trachtenberg Title: General Counsel and Secretary
Address of Collateral Agent:	COLLATERAL AGENT:  OXFORD FINANCE/LC

115 South Union Street Suite 300 Alexandria, VA 22314 Attn: Legal Department

Nams. Colette H. Featherly Title: Sen or Vice President

[Signature Page to First Amendment to IP Security Agreement]

# EXHIBIT A

Patents

PATENT FAMILY: SIL001 THLE(S) TARGETED IN SITU	PATENT FAMILY. SIL001 THEE(S). TARGETED IN SITU THERAPEUTIC DELIVERY OF SECRETED FACTORS FROM STEM CELLS FOR TREATMENT OF DAMAGED TISSUED.	ED FACTORS FROM STEM CELLS F	FOR TREATMENT OF DAMAGED TO	SSUE	
Assignees Board of Trustees of In-ficensed to Combando	Assignees. Board of Trustees of the Leland Stanford Junior University. The U.S. Government Represented by the Department of Veterans Affairs. The Board of Trustees of the University of Illinois in Represented to Combandio	he U.S. Government Represented by t	the Department of Veterans Affairs, T	he Board of Trustees of the Universit	y of illinois
OUR REF NO	APPL'N NO & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO & ISSUE DATE	STATUS
SIL001/US	16/614,205 (United States)	15-Nov-2019	Nat'l Phase of SIL001/WO		PENDING
SIL001/AU	2018269057 (Australia)	18-May-2018	Nat'l Phase of SIL001/WO		PENDING
SIL001/EP	18801734.7 (Europe) [Pub'd as EP3624731 on 25-Mar-	18-May-2018	Nat'l Phase of SIL001/WO		PENDING

PATENT FAMILY: KP005					
TITLE(S): THERAPEUTIC COM	TITLE(S) THERAPEUTIC COMPOUNDS AND USES THEREOF				
Assignee Kala					
OUR REF NO	APPLINIO & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO & ISSUE DATE	STATUS
KP005.A/US	14/768,038	14-Aug-2015	Nat'l Stage of KP005.A/WO	US 9,695,184 on 4-Jul-2017	GRANTED
	(United States)	(371 Date)			
	[Pub'd as US2016/0002254 on 07-				
	Jan-2016]				
KP005.C/US	14/181,095	14-Feb-2014	US ORD of KP005.A &	US 9,353,122 on 31-May-2016	GRANTED
	(United States)		.B/USPR		
	[Pub'd as US2014/0235634 on 21-				
	Aug-2014]				
KP005.C/US2	15/139,099	26-Apr-2016	CON of KP005.C/US	US 9,827,248 on 28-Nov-2017	GRANTED
	(United States)				
	[Pub'd as US2016/0235761 on18-				
	Aug-2016]				

THE STATE OF THE S	AMAGED HSSUE	
ard of Trustees of the Leland Stanford Junior University. The U.S. Government Represented by the ombangio  Appl: N. MO. & COLINTRY EILING DATE	flairs. The Board of Trustees of the Univers	
IR REF. NO. APPLIN NO. & COUNTRY FILING DATE FAMILY RELP	PATENT NO. & ISSUE DATE STATUS	) K
.001/US 16/614,205 15-Nov-2019 Nat'l Phase of SIL001/WO (United States)	WO PENDING	EMAF
.001/AU 2018269057 18-May-2018 Nat'l Phase of SIL001/WO (Australia)	WO PENDING	TDAD
.001/EP         18801734.7         18-May-2018         Nat'l Phase of SIL001/WO           (Europe)         [Pub'd as EP3624731 on 25-Mar-2020]	WO PENDING	

				PATENT FAMILY: KP006  TITLE(S) THERAPEUTIC COMPOUNDS AND USES THEREOF  Assignee Kala	PATENT FAMILY: KP006 TITLE(S) THERAPEUTIC CON Assignee: Kaia
1					
920	JP6669499 on 18-Mar-2020	Nat'l Stage of KP005.C/WO	14-Feb-2014	2015-558148 (Japan) [Pub'd as JP2016513108 on 12- May-2016]	KP005.C/JP
		Validation of KP005.C/EP		(United Kingdom)	KP005.C/GB
		Validation of KP005.C/EP		(France)	KP005.C/FR
		Validation of KP005.C/EP		(Germany)	KP005.C/DE
022	EP2956138 on 22-Jun-2022	Nat'l Stage of KP005.C/WO	14-Feb-2014	14751929.2 (European Patent Office) [Pub'd as EP2956138 on 23-Dec- 2015]	KP005. C/EP
021	CA2900652 on 05-Apr-2021	Nat'l Stage of KP005.C/WO	14-Feb-2014	2,900,652 (Canada) [Pub'd as CA2900652 on 21-Aug- 2014]	KP005.C/CA
ct-201	AU2014216178 on 11-Oct-2018	Nat'l Stage of KP005.C/WO	14-Feb-2014	2014/216,178 (Australia) [Pub'd as AU2014216178 on 03- Sep-2015]	KP005.C/AU
-2021	US 10,966,987 on 06-Apr-2021	CON of KP005.C/US4	25-Jul-2019	16/522,550 (United States) [Pub'd as US2020/0054644 on 20-Feb-2020]	KP005.C/US5
5-2019	US10,398,703 on 03-Sep-2019	CON of KP005.C/US3	11-Jan-2018	15/868,894 (United States) [Pub'd as US2018/0133225 on 17-May-2018]	KP005.C/US4
-2018	US 9,877,970 on 30-Jan-2018	DIV of KP005.C/US	26-Apr-2016	15/139,107 (United States) [Pub'd as US2016/0237093 on 18- Aug-2016]	KP005.C/US3

OUR REF NO	APPL'N NO & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO & ISSUE DATE	STATUS
KP006.C/US	14/184, 886 (United States) [Pub'd as US2014/0235657 on 21-Aug-2014]	20-Feb-2014	US ORD of KP006.A & .B/USPR	US 9,353,123 on 31-May-2016	GRANTED
KP006.C/US2	15/139,121 (United States) [Pub'd as US2016/0235753	26-Apr-2016	CON of KP006.C/US	US 9,833,453 on 5-Dec-2017	GRANTED
KP006.C/US3	15/136,135 (United States) [Pub'd as US2016/0237094 on 18-Aug-2016]	26-Apr-2016	DIV of KP006.C/US	US 9,861,634 on 9-Jan-2018	GRANTED
KP006.C/US4	15/842,695 (United States) [Pub'd as US2018/0104246 on 19-Apr-2018]	14-Dec-2017	CON of KP006.C/US3	US10,285,991 on 14-May-2019	GRANTED
KP006.C/US5	16/361,732 (United States) [Pub'd as US2019/0216812 on 18-Jul-2019]	22-Mar-2019	Con of KP006.C/US4	US10,758,539 on 01-Sep-2020	GRANTED
KP006.C/US6	16/915,508 (United States) [Pub'd as US2020/0323854 on 29-Jun-2020]	29-Jun-2020	CON of KP006.C/US5	US11,369,611 on 28-Jun-2022	GRANTED
KP006.C/US7	17/747,754 (United States)	05-May-2022			PENDING
KP006.C/AU	2014/219,024 (Australia) [Pub'd as AU2014219024 on 05- Apr-2018]	20-Feb-2014	Nat'l Stage of KP006.C/WO	AU2014219024 on 19-Jul-2018	GRANTED
KP006.C/AU2	2018/202,312 (Australia) [Pub'd as AU2018202312 on 26- Apr-2018]	20-Feb-2014	DIV of KP006.C/AU	AU2018202312 on 13-Feb-2020	GRANTED
KP006.C/BR	2015-1120139 (Brazil) [Pub'd as BR112015020139 on 18-Jul-2017]	20-Feb-2014	Nat'l Stage of KP006.C/WO		PENDING
KP006.C/CA	2,900,680 (Canada) [Pub'd as CA2900680 on 28-Aug- 2014]	20-Feb-2014	Nat'l Stage of KP006.C/WO	CA2900680 on 10-Aug-2021	GRANTED

, ()					
PENDING		HK Registration of KP006.C/EP2	20-Feb-2014	42021033402.5 (Hong Kong)	KP006.C/HK-EP2
GRANTED	HK1217191 on 04-May-2021	HK Registration of KP006.C/WO	20-Feb-2014	16105120.4 (Hong Kong) [Pub'd as HK1217191 on 30-Dec- 2016]	KP006.C/HK-EP
PENDING		DIV of KP006.C/EP	20-Feb-2014	20191413.2 (European Patent Office) [Pub'd as EP3763710 on 31-Jan- 2021)	KP006.C/EP2
GRANTED		Valid. of KP006.C/EP		(Netherlands)	KP006.C/EP-NE
GRANTED		Valid. of KP006.C/EP		(Italy)	KP006.C/EP-IT
GRANTED		Valid. of KP006. C/EP		(Ireland)	KP006.C/EP-IE
GRANTED		Valid. of KP006. C/EP		(Great Britain)	KP006.C/EP-GB
GRANTED		Valid. of KP006.C/EP		(France)	KP006.C/EP-FR
GRANTED		Valid. of KP006. C/EP		(Spain)	KP006.C/EP-ES
GRANTED		Valid. of KP006.C/EP		(Germany)	KP006.C/EP-DE
GRANTED		Valid. of KP006.C/EP		(Switzerland)	KP006.C/EP-CH
GRANTED	EP2958895 on 19-Aug-2020	Nat'l Stage of KP006.C/WO	20-Feb-2014	14754329.2 (European Patent Office) [Pub'd as EP2958895 on 30-Dec-2015]	KP006.C/EP
GRANTED	CN105189462 on 10-Nov-2017	Nat'l Stage of KP006.C/WO	20-Feb-2014	2014800212484.8 (China) [Pub'd as CN105189462 on 23- Dec-2015]	KP006.C/CN

KP007.B/EP-DE(Germany)15-Mar-2014Validation of KP007.B/EP	KP007.B/EP         14762750.9         15-Mar-2014         Nat'l Stage of KP007.B/WO           (European Patent Office)         [Pub'd as EP2968274 on 20-Jan-2016]         Nat'l Stage of KP007.B/WO	KP007.B/AU       2014/227737       15-Mar-2014       Nat'l Stage of KP007.B/WO         (Australia)       [Pub'd as AU2014227737 on 17-May-2018]       Nat'l Stage of KP007.B/WO	OUR REF. NO APPL'N NO. & COUNTRY FILING DATE FAMILY REL'P	Assignee Kala	TITLE(S), MEROPENEM DERIVATIVES AND USES THEREOF	PATENT FAMILY KP007
Validation of KP007.B/EP	Nat'l Stage of KP007.B/WO	Nat'l Stage of KP007.B/WO	FAMILY REL'P			
	EP2968274 on 16-Oct-2019	AU2014227737 on 30-Aug- 2018	PATENT NO. & ISSUE DATE			
GRANTED	GRANTED	GRANTED	STATUS			

	[Pub'd as HK40043769 on 24-Sep- 2021]				
KP006.C/IN	2354/MUMNP/2015	20-Feb-2014	Nat'l Stage of KP006.C/WO	IN378043 on 28-Sep-2021	GRANTED
	(India) [Pub'd as IN22/2016 on 27-May- 2016]				
KP006.C/JP2	2018-229512	20-Feb-2014	DIV of KP006.C/JP	JP6830943 on 17-Feb-2021	GRANTED
	(Japan) [Pub'd as JP2019055988 on 11-				
KP006.C/JP4	2022-044906	20-Feb-2014	DIV of KP006.C/JP3		PENDING
	(Japan)				
KP006.CIKR	10-2015-7025432 (South Korea)	20-Feb-2014	Nat'l Stage of KP006.C/WO	KR10-2277833 on 9-July-2021	GRANTED
	[Pub'd as KR20150119361 on 23- Oct-2015]				
KP006.C/MX	MX/a/2015/010829 Mexico	20-Feb-2014	Nat'l Stage of KP006.C/WO	MX368903 on 20-Feb-2020	GRANTED
	[Pub'd as MX2015010829 on 03- Dec-2015]				

KP008.C/EP-DE	KP008.C/EP	KP008.C/AU	OUR REF. NO	Assignee. Kala	PATENT FAMILY: KP008
	(Europ [Pub'd as	[Pub'd as	APPL		PATENT FAMILY: KP008  TITLE(S): NOVEL COMPOUNDS AND USES THEREOF
(Germany)	14807232.5 (European Patent Office) [Pub'd as EP3003314 on 13-Apr- 2016]	2014/275198 (Australia) [Pub'd as AU2014275198 on 10- Dec-2015]	APPL'N NO. & COUNTRY		THEREOF
	30-May-2014	30-May-2014	FILING DATE		
Validation of KP008.C/EP	Nat'l Stage of KP008.C/WO	Nat'l Stage of KP008.C/WO	FAMILY REL'P		
	EP3003314 on 14-May-2019	AU2014275198 on 30-Jul-2017	PATENT NO & ISSUE DATE STATUS		
GRANTED	GRANTED	GRANTED	STATUS		

KP007.B/US3	KP007.B/US2	KP007.B/US	KP007.B/JP2	KP007.B/EP-UK	KP007.B/EP-FR
16/509, 388 (United States) [Pub'd as US2020/0010470 on 09-Jan-2020]	15/650, 667 (United States) [Pub'd as US2017/0349590 on 07-Dec-2017]	14/777,018 (United States) [Pub'd as US2016/0039823 on 11-Feb-2016]	2019-023946 (Japan)	(Great Britain)	(France)
11-ปน1-2019	14-Jul-2017	15-Sep-2015 (371 Date)	15-Mar-2014	15-Mar-2014	15-Mar-2014
CON of KP007.B/US2	CON of KP007.B/US	Nat'l Stage of KP007.B/WO	Div. of KP007.B/JP	Validation of KP007.B/EP	Validation of KP007.B/EP
US11,091,487 on 17-Aug-2021	US10,392,388 on 27-Aug-2019	US 9,725,451 on 8-Aug-2017	JP6738918 on 22-Jul-2020		
GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED

OUR REF. NO	PATENT FAMILY. KP009 TITLE(S), UREA DERIVATIVES AND USES THEREOF Assignee, Kala	KP008.C/US4	N WO. CICCO	NTOVO. CALCOS	KP008.C/US	KP008.C/JP	KP008.C/EP-GB	KP008.C/EP-FR
APPLINIO, & COUNTRY	S AND USES THEREOF	10/4/22, bub (United States) [Pub'd as US2020/0157106 on 21-May-2020]	(United States) [Pub'd as US2019/0023710 on 24-Jan-2019]	(United States) [Pub'd as US2018/0251467 on 06-Sep-2018]	14/894,214 (United States) [Pub'd as US2016/0137646 on 19-May-2016]	2016-517041 (Japan) [Pub'd as JP2016520617 on 14- Jul-2016]	(Great Britain)	(France)
FILING DATE		24-May-2019	7   -MIL-2010	2-May-2010	25-Nov-2015 (371 Date)	30-May-2014		
FAMILY RELIP		DIV of RHOUS.C/US2	CONCLUSION CONCLUSION		Natl Stage of KP008.C/WO	Nat'l Stage of KP008.C/WO	Validation of KP008.C/EP	Validation of KP008.C/EP
PATENT NO. & ISSUE DATE		US1U,954,244 on 23-Mai-2021	OO 10,044, 10 1 011 50-881-5050	03 10,331,370 011 10-011-20 13	US 9,988,386 on 5-Jun-2018	JP6557654 on 19-Jul-2019		
STATUS		GRANIED			GRANTED	GRANTED	GRANTED	GRANTED

2 /22					
GRANTED	JP6469661 on 25-Jan-2019	Nat'l Stage of KP009.C/WO	11-Jun-2014	2016-519614 (Japan)	KP009.C/JP
GRANTED	AU2017219063 on 15-Apr-2021	DIV of KP009.C/AU	24-Aug-2017	2017/219063 (Australia) [Pub'd as AUZ017219063 on 14- Sep-2017]	KP009.C/AU2
GRANTED	AU2014278231 on 7-Sep-2017	Nat'l Stage of KP009.C/WO	11-Jun-2014	2014/278231 (Australia) [Pub'd as AU2014278231 on 24- Dec-2015]	KP009.C/AU
GRANTED	US11,352,343 on 07-Jun-2022	CON of KP009.C/US8	12-Jun-2020	16/900, 657 (United States) [Pub'd as US2020/0299272 on 24-Sep-2020]	KP009.C/US9
GRANTED	US10,723,719 on 28-Jul-2020	CON of KP009.C/US7	01-May-2019	16/400,672 (United States) [Pub'd as US2019/0284172 on 19-Sep-2019]	KP009.C/US8
GRANTED	US 10,329,280 on 25-Jun-2019	CON of KP009.C/US5	26-Jul-2018	16/043,007 (United States) [Pub'd as US2018/0327390 on 15-Nov-2018]	KP009.C/US7
GRANTED	US 10,316,022 on 11-Jun-2019	CON of KP009.C/US5	23-Jul-2018	16/043,000 (United States) [Pub'd as US2018/0327389 on 15-Nov-2018]	KP009.C/US6
GRANTED	US 10,059,693 on 28-Aug-2018	CON of KP009.C/US3	12-Oct-2017	15/782,743 (United States) [Pub'd as US2018/0037573 on 18- Feb-2018]	KP009.C/US5
GRANTED	US 10,059,692 on 28-Aug-2018	CON of KP009.C/US3	12-Oct-2017	15/782,696 (United States) [Pub'd as US2018/0037572 on 18- Feb-2018]	KP009.C/US4
GRANTED	US 9,802,922 on 31-Oct-2017	DIV of KP009.C/US2	20-Jan-2017	15/411,485 (United States) [Pub'd as US2017/0129876 on 11-May-2017]	KP009.C/US3
GRANTED	US 9,580,421 on 28-Feb-2017	DIV of KP009.C/US	12-Nov-2015	14/939,727 (United States) [Pub'd as US 2016/0060264 on 03-Mar-2016]	KP009.C/US2
GRANTED	US 9,212, 145 on 15-Dec-2015	US ORD of KP009,A & .B/USPR	11-Jun-2014	14/301,653 (United States) [Pub'd as US 2015/0072986 on 12-Mar-2015]	KP009.C/US

PATENT FAMILY KP011 THTLE(S) (A+(D) CRYSTALLIN Assignee Kala	PATENT FAMILY: KP011 TITLE(S) (A)-(D): CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF Assignee: Kala	NDS AND USES THEREOF			
OUR REF NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP011.E/US	14/530,092 (United States) [Pub'd as US2015/0125535 on 7-May-2015]	31-Oct-2014	US ORD of Provisionals 1, 3 & 5	US 9,458,169 on 4-Oct-2016	GRANTED
KP011.E/US2	14/981, 105 (United States) IPub'd as US2016/0115176	28-Dec-2015	DIV of KP011.E/US	US 9,790,232 on 17-Oct-2017	GRANTED
	00 26-Apr-20 lb]	,	)));;		) ) ) ! ! !
KP011.E/US3	15/712,645 (United States) [Pub'd as US2018/000982 on 11-Jan-2018]	22-Sep-2017	CON of KP011.E/US2	US 10, 160,765 on 25-Dec-2018	GRANTED
KP011.E/US4	16/184,760 (United States)	08-Nov-2018	CON of KP011.E/US3	US 10,618,906 on 04-Apr-2020	GRANTED
	[Pub'd as US2019/0077810 on 14- Mar-2019]				
KP011.E/US5	16/184,760 (United States)	02-Mar-2020	CON of KP011.E/US4	US10,975,090 on 13-Apr-2021	GRANTED
	(United States) [Pub'd as US2020/0216459 on 09- Jul-2020]				
KP011.E/US6	17/197,702 (United States)	10-Mar-2021	CON of KP011.E/US5		PENDING
	[Pub'd as US2021/0355133 on 18- Nov-2021]				

	[Pub'd as JP2016534030 on 04- Nov-2016]				
KP009.C/JP3	2020-090240 (Japan)	11-Jun-2014	DIV of KP009.C/JP2	JP7058885 on 15-Apr-2022	GRANTED
KP009.C/JP4	2022-063260 (Japan)	11-Jun-2014	DIV of KP009.C/JP3		PENDING

PATENT FAMILY: KP012

TITLE(S), CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

Assignee: Kala

KP011.E/AU	2014/342042	31-Oct-2014	National Stage of KP011.EWO	AU2014342042 on 30-Nov-	GRANTED
	(Australia) Pub'd as AU2014342042 on 12- May-2016]			2017	
KP011.E/CN	201480065624.X	31-Oct-2014	National Stage of KP011.E/WO	CN106061261on 24-Apr-2018	GRANTED
	(China) [Pub'd as CN106061261 on 26-				
	Oct-2016]				
KP011.E/EP	14857737.2	31-Oct-2014	National Stage of KP011.E/WO	EP3062618 on 05-Fe-2020	GRANTED
	(European Patent Office) [Pub'd as EP3062618 on 07-Sep-				
	2016]				
KP011.E/EP-DE	(Germany)		EP validation of KP011.E/EP		GRANTED
KP011.E/EP-FR	France		EP validation of KP011.E/EP		GRANTED
KP011.E/EP-GB	(Great Britain)		EP validation of KP011.E/EP		GRANTED
KP011.E/HK-EP	17102021.0	31-Oct-2014	HK Registration of KP011.E/WO	HK1228197 on 05-Feb-2021	GRANTED
	(Hong Kong) [Pub'd as HK1228197 on 03-Nov- 2017]				
KP011.E/JP	2016-552255	31-Oct-2014	National Stage of KP011.E/WO	JP6426194 on 02-Nov-2018	GRANTED
	(Japan) [Pub'd as JP2016535100] on 10- Nov-2016]				
KP011.E/MX	MX/a/2016/005668	31-Oct-2014	National Stage of KP011.E/WO	MX355330 on 16-Apr-2018	GRANTED
	(Mexico) [Pub'd as MX2016005668 on 28-				
	Oct-2016]				
KP011.E/NZ	719185 (New Zealand)	31-Oct-2014	National Stage of KP011.E/WO	NZ719185 on 27-Feb-2018	GRANTED
	[Pub'd as NZ719185 on 24-Nov- 2017]				

KP013.B/US	OUR REF NO	PATENT FAMILY: KP013 THLE(S)) CRYSTALLINE FOR Assignee Kala		KP012.A/US2		KP012.A/US		KP012.A/JP		KP012.A/AU	OUR REF NO
15/529,969 (United States) [Pub'd as US 2017/0313724	APPLINING & COUNTRY	<b>PATENT FAMILY: KP013</b> TITLE(S)) CRYSTALLINE FORMS OF A THERAPEUTIC COMPOUND AND USES THEREOF Assignes, Kele	(United States) [Pub'd as US2017/0260193 on 14- Sep-2017]	15/604.080	(United States) [Pub'd as US2016/0257693 on 8-Sep-2016]	15/032,595	(Japan) [Pub'd as JP2016535779 on 17- Nov-2016]	2016-552430	(Australia) [Pub'd as AU2014341966 on 12- May-2016]	2014/341966	APPLINIO & COUNTRY
25-May-2017	FILING DATE	ND USES THEREOF	1 1100	24-Mav-2017	(2/-Apr-2016 (371 Date))	3-Nov-2014		3-Nov-2014		3-Nov-2014	FILING DATE
Nat'l Stage of KP013.B/WO	FABILY REL'P			CON KP012.A/US		Nat'l Stage of KP012.AWO		Nat'l Stage of KP012.A/WO		Nat'l Stage of KP012.A/WO	FAMILY REL'P
US 10,253,045 on 09-Apr-2019	PATENT NO & ISSUE DATE			US 9.890.173 on 13-Feb-2018		US 9,688,688 on 27-Jun-2017		JP6426195 on 02-Nov-2018	2017	AU2014341966 on 30-Nov-	PATENT NO & ISSUE DATE
GRANTED	STATUS			GRANTED		GRANTED		GRANTED		GRANTED	STATUS

	ス	0	PATENT FAMILY: KP014 TITLE(S)) A spec UREA D Assignee: Kale
	8	£	88 <b>= 4</b>
	KP014.B/AU	OUR REF NO	PATENT FAMILY: KP014 TITLE(S)) A spec UREA DERIVATIVE AND USES THEREOF; B spec 1-AMINO-TRIAZOLO(1.5-AJPYRIDINE-SUBSTITUTE URE <i>A</i> Assignee Kala
	뭐		* =
	2	- 2	<u>&gt;</u> > ≥
		············	a sp
			" ⊀
			<b>5 5</b>
			₩ 20
			<b>∂ ∓</b>
			$\mathbb{R}$
			₹
			47
			m
		35	Ą
		APPL'N NO & COUNTRY	ð
_	N	- T	8
(Australia)	2015-360,438		m
Str.	ည	O	#
<u>a</u>	9	90	市
_	₽	Ö	A
	ω	₩ ₩	<u>Q</u>
		7	Œ
			<del>2</del> 5
			ø
			<del>, ,</del>
			AW
			<b>2</b>
			O,
			72
	ġ	₩	25 SJ
	Ŕ	翼	Q
	Ÿ	₩.	2
	10-Dec-2015	FILING DATE	<u>→</u> 55
	Ŋ	111	<b>≱</b>
			P *
			Æ
			Z
			m
	$\overline{}$		L S
	Nat'l Stage of KP0	FAMILY REL'P	w Ø
	꺙	<b>#</b>	=
	g	<b>*</b>	Ш
	e 0	m	m
	호	70	菊
	8		m A
	014.B/WO		Q
	8		龙
	8		S
			113
			ATIVE AND USES THEREO
	$\overline{}$		<b>&gt;</b>
	Ç	<b>3</b>	<u> </u>
	2	- 77	Si C
	$\Omega$	<b>5</b>	ហ
	ő	柔	#
	딿	26	剪
	윽	77	Ď
	ζ̈	<u> </u>	Ħ
	1	m	
	₽	2	
	AU2015360438 on 24-Jan-2019   GRANTED		
	19	STATUS	
	유	2	
	Ĭ		
	딆	8	
	Ü		

on 2-Nov-2017]

KP015.A/US	OUR REF. NO	Assignee Kala	PATENT FAMILY: KP015  FITLE(S)) CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
			KP015 FALLINE FORM
15 (Unite) [Pub'd as U 08-N	APPL'N N		S OF THERAPE
15/694,252 (United States) [Pub'd as US2018/0065977 on 08-Mar-2018]	APPL'N NO. & COUNTRY		JTIC COMPOUND
_	F:		S AND USES THE
1-Sep-2017	FILING DATE		REOF
US ORD of KP015.A/USPR	FAMILY REL'P		
015.A/USPR	U		
US 10,336,767 on 2-Jul-2019	PATENT NO & ISSUE DATE STATUS		
	SUE DATE		
GRANTED	STATUS		

US10,875,857 on 29-12-2020
Validation of EP3230272
Validation of EP3230272
Nat'l Stage of KP014.B/WO

KP015.B/US	KP015.A/NZ	KP015.A/KR	KP015.A/EP-HK	KP015.A/EP	KP015.A/CN	KP015.A/CA	KP015.A/BR	KP015.A/AU2	KP015.A/US5	KP015.A/US3	KP015.A/US2
15/694,331 (United States) [Pub'd as US2018/0065978 on 08-Mar-2018]	751277 (New Zealand)	10-2019-7009753 (Korea)	62019000441.1 (Hong Kong) [Pub'd as HK40040593 on 3-Jul- 2020]	17849362.3 (Europe) [Pub'd as EP3509421 on 17-Jul- 2019]	201780055105.9 (China) [Pub'd as CN109688818 on 26- Apr-2019]	3036065 (Canada)	BR112019004463.9 (Brazil)	202017446 (Australia)	17/554,375 (United States) [Pub'd as US2022/0106326 on 07-Apr-2022]	16/818,033 (United States) [Pub'd as US2020/0216460 on 09-Jul-2020]	16/415,848 (United States) [Pub'd as US2019/0270752 on 05-Sep-2019]
1-Sep-2017	1-Sep-2017	1-Sep-2017	26-Dec-2019	1-Sep-2017	1-Sep-2017	1-Sep-2017	1-Sep-2017	1-Sep-2017	17-Dec-2021	13-Mar-2020	17-May-2019
US ORD of KP015.B/USPR	Nat'l phase of KP015.A/WO	Nat'l phase of KP015.AWO	HK registration of KP015.A/EP	Nat'l phase of KP015.AWO	Nat'l phase of KP015.A/WO	Natl phase of KP015.AWO	Nat'l phase of KP015.A/WO	DIV of KP015.A/AU	CON of KP015.A/US4	CON of KP015.A/US2	DIV of KP015.A/US
US 10,253,036 on 09-Apr-2019								AU202017446 on 08-Sept-2022		US11,104,685 on 31-Aug-2021	US 10,626,121 on 21-Apr-2020
GRANTED	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	GRANTED	PENDING	GRANTED	GRANTED

죾	2	Š	==	Q B
KP017.B/CA	OUR REF NO	Assignee: Kala	S	PATENT FAMILY: KP017
ÇÃ	Π Æ	7 Q	<u>m</u>	FA
		Ø	8	₹
			8	Š
			四	Ŧ
			ଦ୍ର	
	APP		7	
(ς ω	- Z - Z		9 A	
3079673 (Canada)	APPL'N NO & COUNTRY		) M	
) da) 73	8		¥	
	3		Ĭ	
			TITLE(S)) BIOCHEMICAL BINDING OF RETS AND VEGERS INHIBITORS	
			8	
6	#			
19-Oct-2018	FILING DATE			
.2018	DATI			
	""			
<u> </u>				
lat'l p	2			
hase	FAMILY REL'P			
Nat'l phase of KP01	Ü			
017.E				
7.B/WO				
	₽ <b>\$</b>			
	PATENT NO & ISSUE DATE STATUS			
	₹			
	00 00			
	Ä			
	Đ m			
PENDING	STAT			
JING	Sñ			
	<u> </u>	<b>1</b>		

KP015.B/US2	15/694,331 (United States) [Pub'd as US2019/0194218 on 27-Jun-2019]	26-Feb-2019	DIV of 15/694,331	US11,021,487 on 01-Jun-2021	GRANTED
KP015.B/US3	17/315,080 (United States) [Pub'd as US2021/0261562 on 26-Aug-2021]	07-May-2021	DIV of KP015.B/US2		PENDING
KP015.B/AU	2017324713 (Australia)	1-Sep-2017	Nat'l phase of KP015.B/WO	AU2017324713 on 26-Nov- 2020	GRANTED
KP015.B/EP	17849363.1 (Europe) [Pub'd as EP3509422 on 17-Jul- 2019]	1-Sep-2017	Natl phase of KP015.B/WO		PENDING
KP015.C/US	15/694,383 (United States) [Pub'd as US2018/0065979 on 08-Mar-2018]	1-Sep-2017	US ORD of KP015.C/USPR	US10,392,399 on 27-Aug-2019	GRANTED
KP015.C/US2	16/513,505 (United States)[Pub'd as US2019/0337963 on 07-Nov-2019]	16-Jul-2019	DIV of KP015.C/US	US10,766,907 on 08-Sep-2020	GRANTED
KP015,C/AU	2017324716 (Australia)	1-Sep-2017	Nat'l phase of KP015.C/WO	AU2017324716 on 26-Nov- 2020	GRANTED
KP015.C/EP	17849365.6 (Europe) [Pub'd as EP3509423 on 17-Jul- 2019]	1-Sep-2017	Nat'l phase of KP015.C/WO		PENDING

KP033.A/USPR	OUR REF NO	PATENT FAMILY KP033 TITLE(S) Coular Therapies Assignee Kala	PATENT FAMILY: KP019	KP017.B/US	KP017.B/NZ	KP017.B/MX	KP017.B/KR	KP017.B/JP	KP017.A/EP-HK	KP017.B/HK-CN	KP017.B/EP	KP017.B/CN
		/ KP033 if Therapies	KP019									
63/298,931 (United States)	APPL'N NO. & COUNTRY			16/757,305 (United States) [Pub'd as US2021/0179582 on 17-Jun-2021]	763580 (New Zealand)	Mx/a/2020/007183 (Mexico)	10-2020-7014314 (South Korea)	(Japan) 2020-521977 (Japan)	62021026025.8 (Hong Kong) [Pub'd as HK40036123 on 21- May-2021]	62021024397.3 (Hong Kong)	EP18801107.6 (Europe) [Pub'd as EP3697775 on 26- Aug-2020]	201880080672.4 (China) [Pub'd as CN11465601A on 28- Jul-2020]
12-Jan-2022	FILING DATE			17-Apr-2020	19-Oct-2018	19-Oct-2018	19-Oct-2018	19-Oct-2018	20-Feb-2021	27-Jan-20121	19-Oct-2018	19-Oct-2018
Provisional	FAMILY REL'P			Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	HK of KP017.A/EP	HK of KP017.B/CN	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO
	PATENT NO & ISSUE DATE			US11,401,260 on 02-Aug-2022								
PENDING	STATUS			GRANTED	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING

KP028/US	OUR REF. NO	PATENT FAMILY: KP028 TITLE(S) Processes for Making Assignee, Combangio	KP036.A/USPR	OUR REF NO	PATENT FAMILY: KP036 THEE(S): Indazole Compounds: Synthesis, and Uses Thereof Assignee: Kala	KP035.A/USPR	OUR REF NO	PATENT FAMILY: KP035 TITLE(S) [1:2:4]Thazolo(4:3-ap Assignee Kala	KP034,A/USPR	OUR REF. NO	PATENT FAMILY: KP034 TITLE(S): Treatment of Neovascular Diseases Assignee: Kala
16/785,463 (United States) [Pub'd as US2020/03254524 on 15-Oct-2020]	APPLINNO & COUNTRY	PATENT FAMILY: KP028 TITLE(S) Processes for Making and Using a Mesenchymal Stem Cell Derived Secretome Assignee: Combangio	63/337,813 (United States)	APPL'N NO. & COUNTRY	Synthesis, and Uses Thereof	63/298,9311 (United States)	APPL'N NO. & COUNTRY	PATENT FAMILY: KP035 TITLE(S): [1,2.4]Tnazoloj4 3-ajpyridine-5-yi Compounds, Synthesis, and Uses Thereof Assignee: Kala	63/335,532 (United States)	APPL'NNO. & COUNTRY	ular Diseases
7.Feb-2020	FILING DATE	Derived Secretome	05-May-2022	FILING DATE		22-Apr-2022	FILING DATE	nd Uses Thereof	27-Apr-2022	FILING DATE	
US ORD Filing of KP028/USPR1 & KP028/USPR2	FAMILY REL'P		Provisional	FAMILY REL'P		Provisional	FAMILY REL'P		Provisional	FAMILY REL'P	
US10,758,571 on 01-SEP-2020	PATENT NO. & ISSUE DATE			PATENT NO & ISSUE DATE			PATENT NO & ISSUE DATE			PATENT NO. & ISSUE DATE	
GRANTED	STATUS		PENDING	STATUS		PENDING	STATUS		PENDING	STATUS	

KP028/US2	16/785,470 (United States) [Pub'd as US2020/03254524 on	7-Feb-2020	US ORD Filing of KP028/USPR1 & KP028/USPR2	US10,758,571 on 01-Sep-2020	GRANTED
KP028/US3	16/842,696	7-Apr-2020	CON of KP08/US2		PENDING
	(United States) [Pub'd as US2020/03254524 on 15-Oct-2020]				
KP028/US4	17/185,801 (United States)	25-Feb-2021	CON of KP089/US3 and CIP of US and US2	US11,129,853 on 28-Sep-2021	GRANTED
	[Pub'd as US2021/0187034 on 24-Jun-2021]				
KP028/AU	2020270892	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
	(Australia) [Pub'd as AU2020270892 on 02- Dec-2021]				
KP028/BR	BR 112021020450-4	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
	(Blazii) [Pub'd as BR112021020450 on 14-Dec-2021]				
KP028/CA	3136614 (Canada)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
	[Pub'd as CÀ3136614 on 5-Nov- 2021]				
KP028/CL	202102655 (Chile)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/CN	202080041151.5 (China)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
	()				
KP028/EP	20788534.4 (Europe)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
	[Pub'd as EP3952892 on 16- Feb-2022]				
KP028/IN	202117051036 (India)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/JP	2021-560632 (Japan)	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
KP028/KR	10-2021-7036569	7-Apr-2020	Nat'l Phase of KP028/WO		PENDING
	(South Korea)	-			!

CUR REF. NO KP030/WO	PATENT FAMILY: KP030 TITLE(S): Lyophilized Mesenchym	KP029/WO	OUR REF. NO	PATENT FAMILY: KP029 TITLE(S) Compositions Comprisit Assignee: Combangio	KP028/NZ	KP028/MX
APPL'N NO. & COUNTRY  PCT/US2021/026159 (PCT) [Pub'd as WO2021/207282 on 14-Oct-2021]	PATENT FAMILY: KP030 TITLE(S): Lyophilized Mesenchymal Stem Cell Derived Secretome and Uses Thereof Assignee: Combangio	PCT/US2022/021617 (PCT)	APPL'N NO. & COUNTRY	PATENT FAMILY: KP029 TITLE(S) Compositions Comprising Branched KGF-2 Derived Peptides and Methods For Use in Ocular Treatment Assignee: Combangio	781988 (New Zealand) [Pub'd as NZ781988 on 16-Feb- 2022]	MX <i>al</i> 2021/012461 (Mexico)
FILING DATE  06-Apr-2021	Uses Thereof	23-Mar-2022	FILING DATE	and Methods For Use in Ocular Tre	7-Apr-2020	7-Apr-2020
PCT Filing of KP030/USPR		PCT filing of KP029/USPR	FAMILY REL'P	atment	Nat'l Phase of KP028/WO	Nat'l Phase of KP028/WO
PATENT NO. & ISSUE DATE			PATENT NO. & ISSUE DATE			
PENDING		PENDING	STATUS		PENDING	PENDING

OUR REF. NO	PATENT FAMILY: KP032 TITLE(S): Processes For Making a Assignee: Combangio	KP031/WO	OUR REF NO	PATENT FAMILY: KP031 TITLE(S): Compositions Comprisin Assignee: Combangio	KP030/KR	KP030/JP	KP030/EP	KP030/CN	
APPLINING & COUNTRY	PATENT FAMILY: KP032 TITLE(S): Processes For Making and Using a Cellular Fibronectin Composition Assignee: Combangio	PCT/US2022/021618	APPL'N NO. & COUNTRY	PATENT FAMILY: KP031 TITLE(S): Compositions Comprising C-Met Agonist Antibodies and Methods For Use in Ocular Treatment Assignee: Combangio	10-2022-7038878 (Korea)	2022-561111 (Japan)	21783770.7 (Europe)	(China)	
FILINGUATE	osition	23-Mar-2022	FILING DATE	ods For Use in Ocular Treatment	06-Apr-2021	06-Apr-2021	06-Apr-2021	06-Apr-2021	
FAMILY KELP		PCT Filing of KP031/USPR	FAMILY REL'P		Nat'l Phase of KP030/WO	Nat'l Phase of KP030/WO	Nat'l Phase of KP030/WO	Nat'l Phase of KP030/WO	
PAIENI NO & ISSUE DATE			PATENT NO & ISSUE DATE						
STATUS		PENDING	SUIVIS		PENDING	PENDING	PENDING	IN PROCESS	

KP030/AU

17/224,068 (United States) [Pub'd as US2021/0369617 on 02-Dec-2021] 2021251785 (Australia)

06-Apr-2021

Nat'l Phase of KP030/WO

US ORD Filing of KP030/USPR

PENDING

PENDING

KP030/US

KP038/USPR1	OUR REF NO	PATENT FAMILY: KP038 TITLE(S): Preparation and Purifica Assignee: Combangio	KP037/USPR1	OUR REF. NO	PATENT FAMILY: KP037 TITLE(S): Methods and Assays for Secretome Activity Analysis Assignee: Combangio		KP032/US2	
63404,455 (United States)	APPLINING & COUNTRY	PATENT FAMILY: KP038 TITLE(S): Preparation and Purification Methods for Mesenchymal Stem Cell Derived Secretome. Assignee: Combangio	63/359,743 (United States)	APPL'N NO. & COUNTRY	Secretome Activity Analysis		17/860,954 (United States)	
07-Sept-2022	FILING DATE	Cell Derived Secretome	8-Jul-2022	FILING DATE			8-1IIF-8	
Provisional	FAMILY REL'P		Provisional	FAMILY REL'P		·		
	PATENT NO & ISSUE DATE			PATENT NO. & ISSUE DATE				
PENDING	STATUS		PENDING	STATUS			PENDING	

KP032/US1

KP032/WO

PCT/US2022/36036 (PCT)

17/856,944 (United States)

1-Jul-2022

US non-provisional of KP032/USPR1 and USPR2

PENDING

PENDING

PCT filing of KP032/USPR1 and USPR2

# EXHIBIT B

Trademarks

Kala Pharmaceuticals, Inc.

Confidential

1/12

8		
-· <b>-</b>		A) ES
KTM001/US (United States)	OUR REF NO	KALA FAMILY: DESCRIPTION:
1/U State	#	Y:
es S	8	101
		₹:
		<b>K</b> ] Res
~	4	eard har
35/9	3	100 That
85/932,177	7	1 nd c
[77	APPLINIO	T leve
		YP lopi
		E: men i dr
		KTM001 TYPE: SERVICE MARK Research and development services and technical of pharmaceuticals and drug formulation technole
<u> </u>	3	SE) Pric
4-7	5	RVI es a mbai
lay-	0	md:
14-May-2013	FILING DATE	MA ech ted
$\omega$	₩	nica mol
		KTM001 TYPE: SERVICE MARK Research and development services and technical coof pharmaceuticals and drug formulation technology
		nsul
	-5	ltati
	É	1 000
42	INT'L CLASS	elati
	2	gni
	Ť.	io th
		ाल की
		KTM001 TYPE: SERVICE MARK  M Research and development services and technical consultation relating to the development and scie of pharmaceuticals and drug formulation technology
	72	nde
4,5	7	ietit
4,585,580	REGISTRATIO NO.	and
580	-	N scii
	9	
		F 7
		ARK: mfic testing
		Si.
12-	BGISTRATIO DATE	
12-Aug-1	541F4	
<u>-14</u>	7 2	
	9	
<b>1</b>		
ZE(	y.	<b>7</b>
REGISTERED	TATES	KALA
Ę	<b>7</b>	LA
ED		

HAILY:  DESCRIPTION: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammaceuticals  DESCRIPTION: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammaceuticals  OURREF NO APPL N NO FILING DATE ENTL CLASS REGISTRATION DATE  KTM002/US 85/932,175 14-May-2013 005 5,401,810 13-Feb-18 REGISTERED				300000000000000000000000000000000000000
KTM002 TYPE: TRADEMARK (character mark)  MARK:  MARK:  HON: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceuticals  Tharmaceuticals  APPLINIO FILING DATE NTL CLASS REGISTRATION DATE  S 85/932,175 14-May-2013 005 5,401,810 13-Feb-18	$\overline{a}$	<b>7</b>		
KTM002 TYPE: TRADEMARK (character mark)  MARK:  MARK:  HON: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceuticals  Tharmaceuticals  APPLINIO FILING DATE NTL CLASS REGISTRATION DATE  S 85/932,175 14-May-2013 005 5,401,810 13-Feb-18	'n	$\Xi$		ほどり
KTM002 TYPE: TRADEMARK (character mark)  MARK:  MARK:  HON: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceuticals  Tharmaceuticals  APPLINIO FILING DATE NTL CLASS REGISTRATION DATE  S 85/932,175 14-May-2013 005 5,401,810 13-Feb-18	ite	$\leq$		<b>X X X I</b>
KTM002 TYPE: TRADEMARK (character mark)  MARK:  MARK:  HON: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceuticals  Tharmaceuticals  APPLINIO FILING DATE NTL CLASS REGISTRATION DATE  S 85/932,175 14-May-2013 005 5,401,810 13-Feb-18	Sp	2		25
KTM002 TYPE: TRADEMARK (character mark)  MARK:  MARK:  HON: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceuticals  Tharmaceuticals  APPLINIO FILING DATE NTL CLASS REGISTRATION DATE  S 85/932,175 14-May-2013 005 5,401,810 13-Feb-18	ta	ž	#	Y
KTM002 TYPE: TRADEMARK (character mark)  MARK:  N: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases: drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceuticals  APPLING. FILING DATE NTLCLASS REGISTRATION DATE  85/932,175 14-May-2013 005 5,401,810 13-Feb-18	tes	$\mathbf{z}$		₫"
KTM002 TYPE: TRADEMARK (character mark)  MARK.  As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceuticals  APPLINO HEING BATE INTLICIASS REGISTRATION REGISTRATION DATE  85/932,175 14-May-2013 005 5,401,810 13-Feb-18	٣			9
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac				*
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac				
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac				<b></b>
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac				Hand 🗷
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac				
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac		œ	2	
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac		5/5		iati
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac		33		# <b>7</b>
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac		<u>'</u>		12 di
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac		75	- 6	38 '5/
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac				Y] 17
TRADEMARK (character mark)  MARK:  armaceutical preparations for use in the treatment of ophthalmological diseases and rug delivery agents in the form of a coating for active ingredients of a pharmaceutical to facilitate the delivery of a pharmaceutical to fac				.s.
REGISTRATION DATE 13-Feb-18				÷ Tha
REGISTRATION DATE 13-Feb-18				麦目
REGISTRATION DATE 13-Feb-18				8-8
REGISTRATION DATE 13-Feb-18		<u>,</u>		₩ E
REGISTRATION DATE 13-Feb-18		4-1		6 E
REGISTRATION DATE 13-Feb-18		Мa		y al
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		<u> </u>		ge pa X
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		20		B Ž Ď
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		13		- E 5
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				R.F IIIS
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				or for
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				ch: Eu
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				ua of
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18			7	ete a c
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		_		1. I.
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		8		na Hir
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		S	-	ng Ea
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				9 5
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				# G
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				ij,ο
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				6.0
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				頭牙
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				7 E
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				##
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		ئر		101
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		40		- 0 <b>S</b>
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		1,8		<b>2</b>
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		316		p# (*
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18		_		₽ <b>2</b>
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				# # # # # # # # # # # # # # # # # # #
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				52
al to facilitate the delivery of a  REGISTRATION  DATE  13-Feb-18				H. B
to facilitate the delivery of a wide range of REGISTRATION STATUS  DATE  13-Feb-18 REGISTERED		13-Feb		<u> </u>
FALA  Gacilitate the delivery of a wide range of GISTRATION STATUS  DATE  13-Feb-18 REGISTERED				<del>7</del>
KALA  cilitate the delivery of a wide range of STRATION STATES  DATE  3-Feb-18 REGISTERED				. <del>.</del>
thate the delivery of a wide range of  RATION STATUS  ALL  Feb-18 REGISTERED				<u> </u>
tte the delivery of a wide range of  AFRON  B  REGISTERED				l lita
the delivery of a wide range of  HON STATUS  REGISTERED		<u>}</u>		<b>7</b>
E delivery of a wide range of  ON  STATUS  REGISTERED		œ		₽
KALA  lelivery of a wide range of  STATUS  REGISTERED				C.
KALA very of a wide range of STATUS REGISTERED				e E
KALA ry of a wide range of STATUS REGISTERED				á
KALA of a wide range of STATUS REGISTERED		Ī		Ž.
KALA a wide range of STATUS REGISTERED		REC		2,
KALA wide range of STATUS EGISTERED				Δ.
Example of TATUS JISTERED				* <b>5</b>
Tange of TERED		SIE		<u> </u>
JA ige of IS		Ĭ		
of ED		뛰		331
		E		<u> </u>
		)		

KTM004/MX 1986902 15-1	<b>KTM004/Brexit</b> UK00917604083 15-1 (UK)	<b>KTM004/EUTM</b> 017604083 15-1 (European Union)	<b>KTM004/CA</b> 1873400 15-1 (Canada)	OUR REF. NO. APPLIANO. FILE	KALA KTM004 TYPE: TRADEMARK (character mark)  FAMILY:  DESCRIPTION: Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for
15-Dec-2017	15-Dec-2017	15-Dec-2017	15-Dec-2017	FILING DATE	TRADEMARK (character mark) utical preparations; topical ophtha
005	005	005	N/A	INT'I CLASS	cter mark) ical ophthalmic pharmaceuti
1860087	UK00917604083	017604083	TMA1,085,451	REGISTRATION	
15-Dec-17	2-May-18	2-May-18	20-Oct-20	REGISTRATION DATE	K: post-surgical treatment of the eye
REGISTERED	REGISTERED	REGISTERED	REGISTERED	STATUS	VYSTALI

Kala Pharmaceuticals, Inc.

Confidential

KTM005/MX (Mexico)	KTM005/Brexit (UK)	KTM005/EUTM (European Union)	KTM005/CA (Canada)	FAMILY: DESCRIPTION: OUR REF. NO	KALA
1986896	UK00917604067	017604067	1873388	Topical ophthalmic pharm	KTM005 TYPE:
15-Dec-2017	15-Dec-2017	15-Dec-2017	15-Dec-2017	neentical preparations: to	TRADEMARK (character mark)
005	005	005	N/A	Topical ophthalmic pharmaceutical preparations: topical ophthalmic pharmaceutical preparation  APPL N.NO FILING DATE INTL CLASS RECESTRA  NO	acter mark)
1860085	UK00917604067	017604067	TMA1,066,019	REGISTRATION	MADO
15-Dec-17	2-May-18	2-May-18	11-Dec-19	MAKK.  s for post-surgical treatment of the eye  HON REGISTRATION  DATE	
REGISTERED	REGISTERED	REGISTERED	REGISTERED	ye STATIS	

KTM007/MX (Mexico)	KTM007/Brexit (UK)	KTM007/EUTM (European Union)	KTM007/CA (Canada)	OUR REE, NO	KALA FAMILY: DESCRIPTION:
1986899	UK00917604059	017604059	1873393	APPL'N NO	KTM007 TYPE: Topical ophthalmic pharm
15-Dec-2017	15-Dec-2017	15-Dec-2017	15-Dec-2017	FILING DATE	TRADEMARK (character mark) accentical preparations, topical ophtha
005	005	005	005	INT'L CLASS	KTN1007 TYPE: TRADEMARK (character mark)  MARK:  Topical ophthalmic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye
1860086	UK00917604059	017604059	TMA1,066,022	REGISTRATION	MARK: utical preparations for the t
15-Dec-2017	2-May-2018	2-May-2018	11-Dec-19	REGISTRATION DATE	reatment of dryness of the s
REGISTERED	REGISTERED	REGISTERED	REGISTERED	STAILS	VISOOVA

Kala Pharmaceuticals, Inc.

3/12

	_		
			~ ~ ~
Ξ.	3		- 72 <b>- 2</b> - 2
7	$\leq$		- X <b>S</b> -
ğ	2		KALA FAMII DESCR
(United States)	KTM009/US2	OUR REF. NO	KALA FAMILY: DESCRIPTION:
ta	$\geq$		₹ 🔨
ŧ	7		
$^{\circ}$	53		
			<u> </u>
			3
		APPL'N NO	₹
	90/749,282		
	3		
	4		
	,9		Ω
	$\tilde{5}$		
	$\approx$		<u> </u>
			0
			5. ₹
			KTM009 TYPE: Pharmaceutical preparation
			i i
	0		~ ~
	Ö		2 2
	÷		
	Ħ		
	Ţ		§ \$
	02		
	02-Jun-2021	FILING DATE	TRADEMARK (character mark) and substances for the treatment of
	_	**************************************	<b>₹</b> 7
			<b>F</b>
			<b>5 5</b>
			ರ ≗
			<b>#</b> 2
			8 #
			— <del>=</del>
			7 3
			<b>3</b> 5
			7 🗲
	_		<u> </u>
	$\geq$		<u>Q</u>
	$\mathcal{L}$	<u></u>	<b>≝</b>
		ENT'L CLASS	=
			₩.
			<b>3</b>
			5
			5
			ric .
			<u> </u>
			<u>=</u>
			₽
			<b>5.</b>
			2
			<del></del>
			5
			<b>.</b>
			8
		REGISTRATIC NO.	9 <b>3</b>
			6 👱
			ASES A
			<b>.</b> .
			<b>CL</b>
			<u> </u>
			<u>₹</u>
			l
			o C
			H Def
			2
		DATE	<b>.</b>
			<b>5</b>
		REGISTRATION DATE	2
			<b>■</b>
			5
			<del></del>
			5
			B
			8
TO ABANDON			2 🖍
	<u> </u>		
	PĮ		
4	PENDING/	STATUS	
3	Ħ		- T
	$\Xi$		0 🗷
	Ž		
$\simeq$	Ð		
$\subseteq$	_		
4			KTM009 TYPE: TRADEMARK (character mark)  Approximately MARK.  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; ophthalmic pharmaceutical preparations.
		<i></i>	

TRADEMARK

REEL: 007935 FRAME: 0231 RECORDED: 12/22/2022